

Aurélien LAMBERT
Born August 6, 1983
31 rue Jeanne d'Arc Nancy (France)
+33 663 883 060
a.lambert@nancy.unicancer.fr
Université de Lorraine, Faculté de Médecine de Nancy
Institut de Cancérologie de Lorraine
RPPS : 10100934495



Academic background

2021: Validation of a **University Hospital Practitioner** position for the start of the 2021 academic year.

2020:

- **Cancer Center Specialist Practitioner** position
- Registration in science thesis (APEMAC EA 4360 Laboratory)

2017-19: **Assistant Head of Hospitals** (ICL) and obtained a Master 2 Biosciences and Health Engineering (Induction of genetic mutations that can be targeted by existing therapeutics in exocrine pancreatic cancer lines using the CrispR-cas9 method) (Pr Merlin, CRAN UMR 7039 laboratory).

2016: Assistant Hospital Specialist (half-time ICL - Epinal)

2016: Title of **Doctor of Medicine** + validation of specialty in **medical oncology** + diploma in medical pedagogy.

2011/2016, **Resident** at the Nancy University Hospital, Medical Oncology specialty:

Metz Emergency Department (Dr Braun), Gynecology (Dr Schweitzer), Hematologic Transplantation Unit - Hematology (Pr Feugier), Medical Oncology (Dr Geoffrois, 2 times), Radiotherapy (Pr Peiffert), Medical Oncology (Dr Spaëth), Medical Oncology (Pr Conroy, 2 times), Tumor Biopathology Department (Pr Merlin).

2007/2011, Second cycle of medical studies: Nancy Faculty of Medicine.

2001/2006:

- First cycle of medical studies.
- Classes préparatoires aux grandes écoles (2 years).
- Scientific baccalaureate.

Publications

B-rank

- **Aurélien Lambert**, Lilian Schwarz, Ivan Borbath, Aline Henry, Jean-Luc Van Laethem, David Malka, Michel Ducreux, Thierry Conroy. An update on treatment options for pancreatic cancer. (Therapeutic Advances in Medical Oncology. 2019).
- **A. Lambert**, M. Jarlier, S. Gourgou-Bourgade, T. Conroy. Response to Folfirinox by Gender in Patients with Metastatic Pancreatic Cancer: Results from the PRODIGE 4/ ACCORD 11 Randomized Trial. (PlosOne 2017).
- **A. Lambert**, C. Gavaille, T. Conroy. Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions (Therapeutic Advances in Gastroenterology, 2017).
- **A. Lambert**, J. Salleron, C. Gavaille, A. Ayav, T. Conroy, V. Laurent. Sarcopenia is an independent prognostic factor for overall survival in patients with pancreatic adenocarcinoma (Scientific reports. 2019. Soumis, en reviewing). (Medical thesis).
- Conroy T, Bachet J-B, Ayav A, Huguet F, **Lambert A**, Caramella C, et al. Current standards and

new innovative approaches for treatment of pancreatic cancer. (European Journal of Cancer. 2016).

- J. Egea, J. Salleron, S. Gourgou-Bourgade, A. Ayav, V. Laurent, T. Conroy, **A. Lambert** A pilot experiment to diagnose progression using a clinical-biological model in the first-line treatment of metastatic pancreatic cancer from the PRODIGE 4 ACCORD 11 clinical trial. (Scientific Reports. 2019. Submitted, reviewing).

C-rank and more

- J. Egea, J. Salleron, T. Conroy, **A. Lambert**. Second-line chemotherapy should be considered for patients with metastatic pancreatic cancer after a good response in first line treatment with FOLFIRINOX regimen (Pancreas. 2019. Submitted, reviewing).
- **A. Lambert**, J. Salleron, C. Gavaille. Local chemotherapy for neoplastic pericardial effusion: a single institution case series and comprehensive review of the literature (Bulletin du Cancer, 2020).
- C. Franczak, A. Witz, K. Geoffroy, M. Flammang, L. Rogerat, J. Demande, M. Rouyer, M. Husson, D. Serre, C. Gavaille, **A. Lambert**, P. Gilson, J.L. Merlin, A. Harlé. Evaluation of KRAS, NRAS and BRAF mutations detection in plasma using an automated molecular diagnostic system for patients with metastatic colorectal cancer. (PlosOne, 2019).
- **A. Lambert**, M. Lion, J. Salleron, M. Rouyer, N. Lozano, J.L. Merlin, A. Harlé. Comparison of Three Real-Time PCR Assays for the Detection of PIK3CA Somatic Mutations in Formalin-Fixed Paraffin Embedded Tissues of Patients with Breast Carcinomas. (Pathology & Oncology Research, 2018).
- **Lambert A**, Conroy T. Standards de chimiothérapie, perspectives et thérapies ciblées dans l'adénocarcinome du pancréas. Oncologie. 2015 Dec 14;17(11-12):519–27.

Oral communications

International meetings:

- **A. Lambert**, J. Salleron, C. Gavaille, A. Ayav, T. Conroy, V. Laurent. Sarcopenia is an independent prognostic factor for overall survival in patients with pancreatic adenocarcinoma. European Congress of Radiology (ECR), **Vienna, Austria**, March 2017.
- **A. Lambert**, Case Study, Retinal Detachment during Sunitinib treatment in patient with renal carcinoma, **Renal Horizon, Athens, Greece**, March 2015.

National meetings:

- **A. Lambert**, J. Salleron, C. Gavaille, A. Ayav, T. Conroy, V. Laurent. Sarcopenia is an independent prognostic factor for overall survival in patients with pancreatic adenocarcinoma, Journées Francophones d'Hépatogastroentérologie et Oncologie Digestive (**JFHOD**), Paris, March 2017.
 - **A. Lambert**, J. Salleron, C. Gavaille, A. Ayav, T. Conroy, V. Laurent. Sarcopenia is an independent prognostic factor for overall survival in patients with pancreatic adenocarcinoma, Journées Françaises de Radiologie (**JFR**), Paris, October 2016.
 - **A. Lambert**, Télésanté, télémédecine, e-santé..., Définitions et application en oncologie, Expérience de terrain, **Congrès de l'AFSOS**, Paris, October 2016.
 - **A. Lambert**, Télésanté, télémédecine, e-santé..., Définitions et application en oncologie, Expérience de terrain, **A. Lambert, Congrès de la FHF**, Lyon, November 2016.
- A. Lambert**, J. Salleron, C. Gavaille, A. Ayav, T. Conroy, V. Laurent. Sarcopenia is an independent prognostic factor for overall survival in patients with pancreatic adenocarcinoma, Cancéropôle Grand EST, Nancy, November 2016.

e-Health

2016-actual: **CEO of PandaLab SAS**, a solution for exchanges between healthcare professionals and for the fluidization of patient pathways in hospitals and cities.

2018: Creation of the **Biotrack project**, supported by a grant from the Merck laboratory, to monitor and improve the management of molecular biology tests.

2017: Finalist for the Unicancer 2017 Innovation Award for the ICLinik project, medical research in 1 click. (Website for addressing patients to benefit from innovative therapeutic trials).

2014: Winner of the Unicancer 2014 innovation jury prize for the creation of the medical smartphone and tablet application MediCL (used daily since).

Training and paramedical

- President of the Scientific Council of the FORCE Fund (Eastern Cancer Research Fund)
- Vice-President of the Association of medical residents of Nancy (LAMIN) since 2012 for 4 years.
- Referent of the commission of the research years at the Faculty of Medicine of Nancy (2015).
- Teacher for an organization of preparation for the ECN (prepECN from 2014 to 2015).
- Teacher for an organization preparing for the 1st year of the medical exam (FormaSup from 2004 to 2008).
- Regular participation in medical oncology teaching:
 - o DES days.
 - o Chemotherapy course at the Gustave Roussy Institute from 13 to 24 January 2014.
 - o Targeted therapy course at the University Hospital of Montpellier in July 2014.
 - o News training in digestive cancerology in Nancy on October 2, 2014.
 - o 12th Monegasque cancer meeting in February 2016.
 - o Clinical exchanges in cancerology TNE-GIST in January 2017.

Languages spoken

French / English (fluent) / German (quickly perfectible) / Russian (novice)

Version January 27, 2021

Dr Aurélien LAMBERT
Oncologie Médicale
RPPS 10100534425
INSTITUT DE CANCÉROLOGIE DE LORRAINE
54519 Vandœuvre-lès-Nancy cedex
T. 03.83.59.65.64 - F. 03.83.59.84.14